CD22

Across TCGA pan-cancer cohorts, CD22 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CD22 data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher CD22 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD22 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

READ, SARC, and ESCA are the cancer types where CD22 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	DFS	Median	All	0.162	0.720	.019	9	view →
SARC	OS	Median	All	0.217	0.772	<.001	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
SKCM	DFS	Median	II,III,IV	0.860	0.661	.019	6	view →
LGG	DFS	Median	All	0.110	0.826	<.001	3	view →
HNSC	OS	Median	All	0.230	0.686	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CD22–READ (DFS)

Open the READ breakdown →